α-Conotoxin ImI (trifluoroacetate salt)
(Synonyms: α-CTx ImI, GCCSDPRCAWRC) 目录号 : GC49140A conotoxin and an antagonist of α7 nAChRs
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
α-Conotoxin ImI is a conotoxin that has been found in C. imperialis and has receptor antagonist and anticancer activities.1 It is a peptide antagonist of homomeric α7 nicotinic acetylcholine receptors (nAChRs; IC50 = 220 nM). α-Conotoxin ImI is selective for α7 nAChRs over α2β2, α3β2, α4β2, α2β4, α3β4, α4β4, and α1β1γδ subunit-containing nAChRs at 5 µM but does inhibit homomeric α9 nAChRs (IC50 = 1,800 nM). Administration of paclitaxel in micelles containing α-conotoxin ImI decreases tumor growth in an MCF-7 mouse xenograft model.2 Intracerebroventricular, but not intraperitoneal, administration of α-conotoxin ImI (20 nmol/animal) induces seizures in rats.3
1.Johnson, D.S., Martinez, J., Elgoyhen, A.B., et al.α-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: Preferential inhibition of homomeric α7 and α9 receptorsMol. Pharmacol.48(2)194-199(1995) 2.Mei, D., Lin, Z., Fu, J., et al.The use of α-conotoxin ImI to actualize the targeted delivery of paclitaxel micelles to α7 nAChR-overexpressing breast cancerBiomaterials4252-65(2015) 3.McIntosh, J.M., Yoshikami, D., Mahe, E., et al.A nicotinic acetylcholine receptor ligand of unique specificity, α-conotoxin ImIJ. Biol. Chem.269(24)16733-16739(1994)
Cas No. | N/A | SDF | |
别名 | α-CTx ImI, GCCSDPRCAWRC | ||
Canonical SMILES | O=C(N[C@H](C(N[C@@H](CSSC[C@@H]1NC([C@H](CSSC[C@@H](NC([C@@H](NC([C@@]2([H])N(CCC2)C([C@@H](NC([C@@H](NC1=O)CO)=O)CC(O)=O)=O)=O)CCCNC(N)=N)=O)C(N[C@H](C(N3)=O)C)=O)NC(CN)=O)=O)C(N)=O)=O)CCCNC(N)=N)[C@@H]3CC4=CNC5=CC=CC=C45.FC(F)(C(O)=O)F | ||
分子式 | C52H78N20O15S4·XCF3COOH | 分子量 | 1351.6 |
溶解度 | Water: soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.7399 mL | 3.6993 mL | 7.3986 mL |
5 mM | 0.148 mL | 0.7399 mL | 1.4797 mL |
10 mM | 0.074 mL | 0.3699 mL | 0.7399 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。